Table of Contents
1 Table of Contents 3
1.1 List Of Tables 6
1.2 List of Figures 7
2
Company Overview 8
2.1 Key Information 8
2.2 Industry Outlook -- In
Vitro Diagnostics 8
3 Major Products and Services 9
3.1 Overview 9
4 Competitors 10
5 Key Employees 11
6 Locations And Subsidiaries
12
6.1 Head Office 12
7 Recent Developments 13
7.1 Product News
13
7.1.1 Feb 07, 2008: BG Medicine Gains Rights To Test For
Atherothrombosis Biomarker 13
7.1.2 Feb 05, 2008: BG Medicine Acquires
Exclusive Commercial Rights To Biomarker Of Vascular Plaque 13
7.1.3 Sep
18, 2007: Spinal Muscular Atrophy Foundation And BG Medicine Announce
Collaboration 13
7.1.4 May 23, 2007: BG Medicine Acquires Exclusive Rights
to Biomarkers of Congestive Heart Failure from ACS Biomarker 14
7.1.5 May
16, 2007: BG Medicine and Multiple Sclerosis Research Center of New York
Announce Collaboration 14
8 BG Medicine, Inc. Pipeline Products 15
8.1
BG Medicine, Inc. Product Pipeline Analysis 15
8.1.1 BG Medicine, Inc.
Pipeline Products By Equipment Type 15
8.1.2 BG Medicine, Inc. Pipeline
Products By Development Stage 16
8.1.3 BG Medicine, Inc. Pipeline Products
By Therapy Area 17
8.1.4 BG Medicine, Inc. Pipeline Products By News
Summary 17
8.2 Liver Toxicity Biomarker 17
8.2.1 Product Description
18
8.2.2 Product Institution Details 18
8.2.3 Product Status 18
8.2.4 Product Milestone 18
8.3 Plasma biomarkers 19
8.3.1 Product
Description 19
8.3.2 Product Institution Details 19
8.3.3 Product
Status 19
8.3.4 Product Milestone 19
8.4 Biomarker-based Molecular
Diagnostic Test For Congestive Heart Failure 20
8.4.1 Product Description
20
8.4.2 Product Status 20
8.4.3 Product Milestone 20
8.5
Biomarkers for multiple sclerosis 21
8.5.1 Product Description 21
8.5.2 Product Status 21
8.5.3 Product Milestone 21
8.6 Biomarker for
acute atherothrombosis 22
8.6.1 Product Description 22
8.6.2 Product
Status 22
8.6.3 Product Milestone 22
8.7 Biomarker for Herceptin
treatment 23
8.7.1 Product Description 23
8.7.2 Product Status 23
8.8 Biomarker for early response to Tykerb 24
8.8.1 Product Description
24
8.8.2 Product Status 24
8.9 Biomarkers for Alzheimer' s disease
24
8.9.1 Product Description 24
8.9.2 Product Status 25
8.10
Markers for Tysabri efficacy 25
8.10.1 Product Description 25
8.10.2
Product Status 25
8.11 Biomarker of response to Avastin treatment 25
8.11.1 Product Description 25
8.11.2 Product Status 26
8.12 Molecular
diagnostic test for Avandia treatment 26
8.12.1 Product Description 26
8.12.2 Product Status 26
8.13 Biomarker for detection of preeclampsia
27
8.13.1 Product Description 27
8.13.2 Product Status 27
8.14
Biomarkers for Enbrel and Remicade treatment 27
8.14.1 Product Description
27
8.14.2 Product Status 28
8.15 Diagnostic tests(acute
atherothrombosis) 28
8.15.1 Product Description 28
8.15.2 Product
Status 28
8.15.3 Product Milestone 28
9 Appendix 30
9.1
Methodology 30
9.1.1 Coverage 30
9.1.2 Secondary Research 31
9.1.3
Primary Research 31
9.1.4 Expert Panel Validation 32
9.2 Contact Us
32
9.3 About Global Markets Direct 32
9.4 Disclaimer 32
1.1
List of Tables
Table 1: BG Medicine, Inc.,Key Facts 8
Table 2:
BG Medicine, Inc., Key Employees, 11
Table 3: BG Medicine, Inc.
Pipeline Products by Equipment Type 15
Table 4: BG Medicine, Inc.
Pipeline Products By Development Stage 16
Table 5: BG Medicine, Inc.
Pipeline Products By Therapy Area 17
Table 6: BG Medicine, Inc.
Pipeline Products By News Summaries 17
1.2 List of Figures
Figure
1: BG Medicine, Inc. Pipeline Products By Development Stage 16
Figure
2: Global Markets Direct Methodology 30
View Cart
